Clinical trial • Phase III • Infectious Disease|Other
Clinical trial in Urinary tract infection
Phase III trial for Urinary tract infection. 14 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease|Other
- Trial Disease
- Urinary tract infection
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 13-05-2025
- First CTIS Authorization Date
- 14-07-2025
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 14
Recruitment
- Planned Sample Size
- 14
- Recruitment Window Months
- 13
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 14
Germany
- Earliest CTIS Part Ii Submission Date
- 17-06-2025
- Latest Decision Or Authorization Date
- 14-07-2025
- Processing Time Days
- 27
- Number Of Sites
- 1
- Number Of Participants
- 14
Sites
- Site Name
- Justus-Liebig-Universitaet Giessen
- Department Name
- Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie
- Principal Investigator Name
- Florian Wagenlehner
- Principal Investigator Email
- florian.wagenlehner@chiru.med.uni-giessen.de
- Contact Person Name
- Florian Wagenlehner
- Contact Person Email
- florian.wagenlehner@chiru.med.uni-giessen.de
- Number Of Participants
- 14
Sponsor
Primary sponsor
- Full Name
- Schaper & Bruemmer GmbH & Co. KG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Related trials
Other published trials that may interest you.
- GEPOTIDACIN for Urinary tract infection
- GSKVX000000044501 for Urinary tract infection
- CD40.Pan.CoV vaccine for Healthy volunteers
- CIPROFLOXACIN for Urinary tract infection with systemic involvement|Complicated urinary tract infection|Acute pyelonephritis|Bacterial prostatitis
- Amoxicillin; clavulanic acid for Febrile urinary tract infection|Urinary tract infection